Avidity Biosciences GAAP EPS of -$1.27 misses by $0.16, revenue of $12.48M [Seeking Alpha]
Avidity Biosciences, Inc. (RNA)
Company Research
Source: Seeking Alpha
Novartis' Deal For Avidity And Its Late-Stage Muscle Disease Assets Has Caveats Novartis' Avidity Deal: Growth Accretive, Multiple Gated By Execution Avidity Biosciences: Maintaining 'Strong Buy' Rating Based On Accelerated Approval Filing For Del-Zota Key deals this week: Qorvo, Chewy, Sotherly Hotels, Novartis, CSG Systems, and more Avidity stock surges on $12B Novartis deal
Show less
Read more
Impact Snapshot
Event Time:
RNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNA alerts
High impacting Avidity Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
RNA
News
- Avidity Biosciences, Inc. (RNA): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-WTRG, RNA, FIZN, and TCBXPR Newswire
- Novartis sees sales boost from key cancer drugs [Yahoo! Finance Canada]Yahoo! Finance Canada
- Novartis targets 5%-6% annual sales growth until 2030 on key cancer drugs [CNBC]CNBC
- Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44PR Newswire
RNA
Earnings
- 11/10/25 - Miss
RNA
Sec Filings
- 12/5/25 - Form SCHEDULE
- 11/24/25 - Form PREM14A
- 11/20/25 - Form DEFA14A
- RNA's page on the SEC website